Trillium Therapeutics signs pact with Genentech

Guest Contributor
December 21, 2004

Trillium Therapeutics Inc has entered into an agreement with biotech giant Genentech Inc, San Francisco, to develop and commercialize its technology in the area of protein therapeutics. The exact nature of the technology and the terms of the agreement were not disclosed. The agreement will provide privately held Trillium with an upfront payment, research funding and milestone payments. Genentech will be solely responsible for clinical development, regulatory approvals, manufacturing and commercialization. Trillium — formerly called Transplantation Technologies Inc — was formed in 1996 by five Toronto and London-based research institutions. Its initial focus on xenotransplantation was subsequently expanded to include various areas of immunology. In 2002 it received $7.5 million in first round financing from Canadian Medical Discoveries Fund, Business Development Bank of Canada and VenGrowth Advanced Life Sciences Fund Inc. The same investors invested another $6 million in early 2004....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.